Study Of Healthy Subjects To Assess The Effect Of Ketoconazole And The Way The Body Will React To Casopitant [GW679769]

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

October 20, 2006

Primary Completion Date

January 5, 2007

Study Completion Date

January 5, 2007

Conditions
Nausea and Vomiting, Chemotherapy-Induced
Interventions
DRUG

ketoconazole

Ketoconazole tablets will be available with dose strength of 200 mg. The dose of ketoconazole 400 mg will be comprised of two 200 mg tablets. On Day 4 of Treatment Period 2, the dose of casopitant and ketoconazole is to be taken at the same time.

DRUG

casopitant 100 mg

Casopitant tablets will be available with dose strength of 50 mg. Subjects will receive two 50 mg tablets for the dose of 100 mg. On Day 4 of Treatment Period 2, the dose of casopitant and ketoconazole is to be taken at the same time

DRUG

Casopitant 50 mg

Casopitant tablets will be available with dose strength of 50 mg and will receive single dose. On Day 4 of Treatment Period 2, the dose of casopitant and ketoconazole is to be taken at the same time.

Trial Locations (1)

66219

GSK Investigational Site, Lenexa

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY